Morgan Stanley
LABD icon

Morgan Stanley’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History

Morgan Stanley’s Portfolio LABD Stock Details LABD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.78K Buy
+600
New +$11.4K ﹤0.01% 6951
2025
Q4 		– Sell
-15
Closed -$607 – 8357
2025
Q3 		$607 Sell
15
-404
-96% -$23.4K ﹤0.01% 7464
2025
Q2 		$31.3K Sell
419
-475
-53% -$42K ﹤0.01% 6508
2025
Q1 		$84.3K Buy
894
+33
+4% +$2.42K ﹤0.01% 6091
2024
Q4 		$62.4K Buy
861
+34
+4% +$2.08K ﹤0.01% 6221
2024
Q3 		$48.3K Sell
827
-1,152
-58% -$70K ﹤0.01% 6229
2024
Q2 		$145K Buy
1,979
+417
+27% +$35.2K ﹤0.01% 5811
2024
Q1 		$114K Buy
1,562
+639
+69% +$53.3K ﹤0.01% 5935
2023
Q4 		$89.4K Buy
923
+814
+747% +$158K ﹤0.01% 6200
2023
Q3 		$22.4K Sell
109
-3,680
-97% -$598K ﹤0.01% 6445
2023
Q2 		$544K Buy
3,789
+2,932
+342% +$438K ﹤0.01% 5170
2023
Q1 		$177K Sell
857
-636
-43% -$108K ﹤0.01% 5760
2022
Q4 		$258K Sell
1,493
-312
-17% -$63.9K ﹤0.01% 5564
2022
Q3 		$432K Buy
1,805
+1,534
+566% +$356K ﹤0.01% 5338
2022
Q2 		$106K Sell
271
-5
-2% -$2.51K ﹤0.01% 6239
2022
Q1 		$97K Sell
276
-580
-68% -$227K ﹤0.01% 6327
2021
Q4 		$220K Buy
856
+290
+51% +$66.7K ﹤0.01% 6018
2021
Q3 		$120K Buy
566
+247
+77% +$52.5K ﹤0.01% 6267
2021
Q2 		$61K Sell
319
-230
-42% -$51.6K ﹤0.01% 6586
2021
Q1 		$119K Sell
549
-232
-30% -$45K ﹤0.01% 5919
2020
Q4 		$197K Buy
781
+548
+235% +$209K ﹤0.01% 5597
2020
Q3 		$139K Sell
233
-31
-12% -$20K ﹤0.01% 5275
2020
Q2 		$183K Buy
264
+230
+676% +$289K ﹤0.01% 5118
2020
Q1 		$96K Sell
34
-253
-88% -$722K ﹤0.01% 5203
2019
Q4 		$708K Sell
287
-1,814
-86% -$6.44M ﹤0.01% 4735
2019
Q3 		$10.6M Sell
2,101
-81
-4% -$333K ﹤0.01% 2055
2019
Q2 		$7.86M Buy
2,182
+20
+0.9% +$84.2K ﹤0.01% 2424
2019
Q1 		$7.95M Sell
2,162
-96
-4% -$465K ﹤0.01% 2265
2018
Q4 		$19.3M Sell
2,258
-293
-11% -$2.15M 0.01% 1491
2018
Q3 		$12.4M Buy
2,551
+402
+19% +$1.94M ﹤0.01% 2193
2018
Q2 		$11.1M Buy
2,149
+1,058
+97% +$6.42M ﹤0.01% 2256
2018
Q1 		$7.96M Buy
1,091
+876
+407% +$6.09M ﹤0.01% 2565
2017
Q4 		$1.98M Buy
+215
New +$2.14M ﹤0.01% 4040
2017
Q3 		– Sell
-2
Closed -$24.1K – 6404
2017
Q2 		$25K Buy
2
+1
+100% +$19.2K ﹤0.01% 6040
2017
Q1 		$21K Hold
1
– – ﹤0.01% 6074
2016
Q4 		$40K Hold
1
– – ﹤0.01% 5811
2016
Q3 		$37K Sell
1
-2
-67% -$93.5K ﹤0.01% 5703
2016
Q2 		$243K Buy
+3
New +$242K ﹤0.01% 4842
2016
Q1 		– Hold
0
– – – 5792

Other funds holding LABD

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
CCM
Capstone Capital Management Hong Kong $224M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley's LABD Position: Q1 2026 in Review

Morgan Stanley opened a new position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) in Q1 2026: 600 shares worth $9.78K. The stake represents ﹤0.01% of the portfolio and ranks #6951 among its holdings. This is a return to the name: Morgan Stanley previously reported a position in LABD as recently as Q3 2025.

Morgan Stanley first reported a position in LABD in Q2 2016 and has held it in 38 quarters since. The position peaked at $19.3M in Q4 2018. 17 funds tracked by Wall St. Rank hold LABD as of Q1 2026.

  • Morgan Stanley held 600 shares of Direxion Daily S&P Biotech Bear 3X ETF worth $9.78K as of Q1 2026.
  • Direxion Daily S&P Biotech Bear 3X ETF was a new Morgan Stanley position in Q1 2026.
  • Direxion Daily S&P Biotech Bear 3X ETF made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6951 holding.
  • Morgan Stanley first reported a position in Direxion Daily S&P Biotech Bear 3X ETF in Q2 2016 and has held it in 38 quarters since.
  • Morgan Stanley's Direxion Daily S&P Biotech Bear 3X ETF position peaked at $19.3M in Q4 2018.
  • 17 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.